Ceryvyn Therapeutics (ASX:CYV) Interest Received: A$8.94 Mil (TTM As of Jun. 2025)


What is Ceryvyn Therapeutics Interest Received?

Ceryvyn Therapeutics ASX:CYV -7.69% Interest Received is A$8.94 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Ceryvyn Therapeutics's Interest Received for the six months ended in Jun. 2025 was A$2.94 Mil.

Ceryvyn Therapeutics's Interest Received for the trailing twelve months (TTM) ended in Jun. 2025 was A$8.94 Mil.

Ceryvyn Therapeutics Interest Received Related Terms

Ceryvyn Therapeutics Interest Received Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Interest Received Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Received
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.31 4.65 4.94 8.78

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Interest Received Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.37 2.68 2.23 6.00 2.94

Ceryvyn Therapeutics Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$8.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Received →
What does a Interest Received of A$8.94 Mil mean?
Ceryvyn Therapeutics (ASX:CYV) has a Interest Received of A$8.94 Mil as of Jun. 2025. Interest Received represents interest received by the company in direct cash flow method. View historical data for Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Interest Received too high?
Ceryvyn Therapeutics' current Interest Received is A$8.94 Mil.
How does Ceryvyn Therapeutics' Interest Received compare to VRTX and REGN?
Ceryvyn Therapeutics' Interest Received of A$8.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Received for a Biotechnology company?
A good Interest Received depends on the Biotechnology industry context. However, Interest Received should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Received mean?
A high Interest Received can signal that a stock is expensive relative to its fundamentals. Interest Received represents interest received by the company in direct cash flow method. View historical data for Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Interest Received is A$8.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Interest Received of A$8.94 Mil. The current Interest Received is A$8.94 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Received calculated?
Interest Received is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Interest Received is A$8.94 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.